Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 237

1.

Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.

He Y, Wu AC, Harrington BS, Davies CM, Wallace SJ, Adams MN, Palmer JS, Roche DK, Hollier BG, Westbrook TF, Hamidi H, Konecny GE, Winterhoff B, Chetty NP, Crandon AJ, Oliveira NB, Shannon CM, Tinker AV, Gilks CB, Coward JI, Lumley JW, Perrin LC, Armes JE, Hooper JD.

Oncogene. 2015 Apr 20. doi: 10.1038/onc.2015.101. [Epub ahead of print]

PMID:
25893298
2.

Clinical and pathological characterization of endometrial cancer in young women: Identification of a cohort without classical risk factors.

Burleigh A, Talhouk A, Gilks CB, McAlpine JN.

Gynecol Oncol. 2015 Apr 12. pii: S0090-8258(15)00793-3. doi: 10.1016/j.ygyno.2015.02.028. [Epub ahead of print]

PMID:
25870916
3.

Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum.

Singh N, Gilks CB, Wilkinson N, McCluggage WG.

Histopathology. 2015 Jan 14. doi: 10.1111/his.12651. [Epub ahead of print]

PMID:
25640750
4.

Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.

McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, McAlpine JN.

Gynecol Oncol. 2015 Jan 28. pii: S0090-8258(15)00584-3. doi: 10.1016/j.ygyno.2015.01.541. [Epub ahead of print]

PMID:
25636458
5.

FOXL2 Mutation is Absent in Uterine Tumors Resembling Ovarian Sex Cord Tumors.

Chiang S, Staats PN, Senz J, Kommoss F, De Nictolis M, Huntsman DG, Gilks CB, Oliva E.

Am J Surg Pathol. 2015 May;39(5):618-23. doi: 10.1097/PAS.0000000000000367.

PMID:
25581731
6.

Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy.

Kwon JS, McAlpine JN, Hanley GE, Finlayson SJ, Cohen T, Miller DM, Gilks CB, Huntsman DG.

Obstet Gynecol. 2015 Feb;125(2):338-45. doi: 10.1097/AOG.0000000000000630.

PMID:
25568991
7.

Loss of Sprouty2 in human high-grade serous ovarian carcinomas promotes EGF-induced E-cadherin down-regulation and cell invasion.

So WK, Cheng JC, Fan Q, Wong AS, Huntsman DG, Gilks CB, Leung PC.

FEBS Lett. 2015 Jan 30;589(3):302-9. doi: 10.1016/j.febslet.2014.12.012. Epub 2014 Dec 20.

PMID:
25533808
8.

Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas.

Gilks CB, Irving J, Köbel M, Lee C, Singh N, Wilkinson N, McCluggage WG.

Am J Surg Pathol. 2015 Mar;39(3):357-64. doi: 10.1097/PAS.0000000000000353.

PMID:
25517954
9.

Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.

Hanna WM, Barnes PJ, Chang MC, Gilks CB, Magliocco AM, Rees H, Quenneville L, Robertson SJ, SenGupta SK, Nofech-Mozes S.

J Clin Oncol. 2014 Dec 10;32(35):3967-73. doi: 10.1200/JCO.2014.55.6092. Epub 2014 Nov 10.

PMID:
25385731
10.

HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.

Sheffield BS, Garratt J, Kalloger SE, Li-Chang HH, Torlakovic EE, Gilks CB, Schaeffer DF.

Arch Pathol Lab Med. 2014 Nov;138(11):1495-502. doi: 10.5858/arpa.2013-0604-OA.

PMID:
25357111
11.

Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry: guidelines for the preparation, release, and storage of unstained archived diagnostic tissue sections for immunohistochemistry.

Cheung CC, Banerjee D, Barnes PJ, Berendt RC, Butany J, Canil S, Clarke BA, El-Zimaity H, Garratt J, Geldenhuys L, Gilks CB, Manning L, Mengel M, Perez-Ordonez B, Pilavdzic D, Riddell R, Swanson PE, Torlakovic EE.

Am J Clin Pathol. 2014 Nov;142(5):629-33. doi: 10.1309/AJCP77GXYVEQXMXT.

PMID:
25319977
12.

Targeted mutation analysis of endometrial clear cell carcinoma.

Hoang LN, McConechy MK, Meng B, McIntyre JB, Ewanowich C, Gilks CB, Huntsman DG, Köbel M, Lee CH.

Histopathology. 2015 Apr;66(5):664-74. doi: 10.1111/his.12581. Epub 2015 Jan 13.

PMID:
25308272
13.

Current morphologic criteria perform poorly in identifying hereditary leiomyomatosis and renal cell carcinoma syndrome-associated uterine leiomyomas.

Alsolami S, El-Bahrawy M, Kalloger SE, AlDaoud N, Pathak TB, Chung CT, Mulligan AM, Tomlinson IP, Pollard PJ, Gilks CB, McCluggage WG, Clarke BA.

Int J Gynecol Pathol. 2014 Nov;33(6):560-7. doi: 10.1097/PGP.0000000000000091. Erratum in: Int J Gynecol Pathol. 2015 Mar;34(2):213. Cheung, Catherine T [corrected to Chung, Catherine T].

PMID:
25272294
14.

Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas.

Hoang LN, Ali RH, Lau S, Gilks CB, Lee CH.

Int J Gynecol Pathol. 2014 Sep;33(5):483-91. doi: 10.1097/PGP.0b013e31829ff239.

PMID:
25083964
15.

TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data.

Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, Melnyk N, McPherson A, Bashashati A, Laks E, Biele J, Ding J, Le A, Rosner J, Shumansky K, Marra MA, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP.

Genome Res. 2014 Nov;24(11):1881-93. doi: 10.1101/gr.180281.114. Epub 2014 Jul 24.

16.

Absence of BRCA/FMR1 correlations in women with ovarian cancers.

Gleicher N, McAlpine JN, Gilks CB, Kushnir VA, Lee HJ, Wu YG, Lazzaroni-Tealdi E, Barad DH.

PLoS One. 2014 Jul 18;9(7):e102370. doi: 10.1371/journal.pone.0102370. eCollection 2014.

17.

The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.

Chui MH, Ryan P, Radigan J, Ferguson SE, Pollett A, Aronson M, Semotiuk K, Holter S, Sy K, Kwon JS, Soma A, Singh N, Gallinger S, Shaw P, Arseneau J, Foulkes WD, Gilks CB, Clarke BA.

Am J Surg Pathol. 2014 Sep;38(9):1173-81. doi: 10.1097/PAS.0000000000000298.

PMID:
25025451
18.

Expanding the morphologic spectrum of differentiated VIN (dVIN) through detailed mapping of cases with p53 loss.

Singh N, Leen SL, Han G, Faruqi A, Kokka F, Rosenthal A, Jiang XR, Kim R, McAlpine JN, Gilks CB.

Am J Surg Pathol. 2015 Jan;39(1):52-60. doi: 10.1097/PAS.0000000000000291.

PMID:
25025443
19.

Mutations in oncogenes: context matters.

Gilks CB.

Gynecol Oncol. 2014 Jul;134(1):1-2. doi: 10.1016/j.ygyno.2014.05.023. No abstract available.

PMID:
24952407
20.

Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal.

Singh N, Gilks CB, Wilkinson N, McCluggage WG.

Histopathology. 2014 Aug;65(2):149-54. doi: 10.1111/his.12419. Epub 2014 May 20. Review.

PMID:
24660659
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk